Examples of NIH Agreement in a sentence
Without limiting the foregoing, the obligations set forth on Schedule 11.3 with respect to the NIH Agreement shall be binding upon Genzyme as if Genzyme were a party to the NIH Agreement.
With respect to AR54 only, UP agrees and acknowledges that the Licensed Technology and AltaRex’s grant hereunder, excludes any and all rights granted to AltaRex under the Public Health Service Patent License Agreement entered into between the National Institutes of Health and AltaRex effective as of September 11, 1999 (the “NIH Agreement”) and which NIH Agreement expires as of June 11, 2002.
Note: The annual royalty payment, including 2020 (payable upfront), is subject to a minimum of US$15,000 payable on the anniversary of execution of the License Agreement to reimburse T-Cure for annual minimum royalty payments due from T-Cure to the NIH under the NIH Agreement.
Upon AltaRex's receipt prior to June 11, 2002 of UP's written notice that UP would like to sublicense the rights to such NIH Materials granted to AltaRex under the NIH Agreement, such Materials shall automatically be included in Licensed Technology.
This conversion is subject to IC approval, which Kite shall use commercially reasonable efforts to obtain on behalf of the Company, and contingent upon acceptance by the Company of the remaining provisions of the NIH Agreement.
Pursuant to Paragraph 4.3 of the NIH Agreement, upon termination of the NIH Agreement under Article 13 thereof, DS’s sublicense under the NIH Agreement shall terminate or convert to a license directly between DS and the IC, at the option of DS.
BSC and Cook each agree to provide any additional information reasonably requxxxx by Angiotech to evaluate their respective performance under this Agreement and to allow Angiotech to fulfill its obligations under the NIH Agreement.
Angiotech shall be entitled to fi1e, prosecute and maintain in force any and all patents and patent applications included in the Patent Rights (excluding the NIH Patent Rights which are governed by the NIH Agreement); provided, that with respect to the Angiotech Patent Rights, Angiotech will provide BSC and Cook a reasonable opportunity to review and comment on the same.
As required by Paragraph 4.2 of the NIH Agreement, Paragraphs 5.1-5.4, 8.1, 10.1, 10.2, 12.5, and 13.8-13.10 of the NIH Agreement, to the extent applicable, shall be binding upon DS as if DS were a party to the NIH Agreement.
With respect to AR54 only, UP agrees and acknowledges that the Licensed Technology and AltaRex's grant hereunder, excludes any and all rights granted to AltaRex under the Public Health Service Patent License Agreement entered into between the National Institutes of Health and AltaRex effective as of September 11, 1999 (the "NIH Agreement") and which NIH Agreement expires as of June 11, 2002.